About Dermata Therapeutics, Inc. - Common Stock (DRMA)
Dermata Therapeutics Inc is a biotechnology company focused on developing innovative therapeutics for skin diseases and conditions. The company leverages its proprietary technology platform to create treatments that aim to improve patient outcomes in dermatology. Dermata Therapeutics is committed to addressing unmet medical needs and advancing its product candidates through various stages of clinical development. By prioritizing research and development, the company seeks to bring forward effective solutions for skin health and enhance the quality of life for individuals affected by dermatological disorders. Read More
DALLAS, TX – October 15, 2026 – Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) announced major advancements in its next-generation G®CELLS Graphene Aluminum-Ion Battery technology, reporting a 48% increase in energy density, doubling of cycle life to 1,000 cycles and 94% energy efficiency during six-minute fast charging . The results could strengthen GMG's position in the growing markets for advanced battery technology, industrial energy storage and rapid-charging applications .
- Once-weekly Tome Foundational Treatment demonstrated improvements across key measures of skin appearance after four treatments -- Over 71% of study participants were graded as having overall improvements in their skin after only one treatment -- Tome Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time -
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
